A-Synaptic Pharma

Executive Summary

A-Synaptic Pharma is a private early-stage biotechnology company based in Cambridge, MA, developing a proprietary prescriptive topical transdermal delivery platform for precise systemic and local targeting of cannabinoid active pharmaceutical ingredients (APIs). Founded in 2021, the company focuses on creating prescription drugs for orphan conditions and areas of major unmet medical need. Their technology aims to overcome bioavailability and dosing challenges associated with cannabinoids, potentially enabling novel therapeutic applications. As a pre-revenue startup with no disclosed funding or pipeline details, A-Synaptic faces typical early-stage risks including development timelines and regulatory uncertainty. Nonetheless, its transdermal delivery approach aligns with growing interest in cannabinoid-based therapies and precision drug delivery.

Upcoming Catalysts (preview)

• TBDAnnouncement of lead candidate development milestone30% success
• TBDSecuring seed or Series A financing40% success
• TBDPresentation of preclinical proof-of-concept data35% success